The glycobiology of brain tumors: Disease relevance and therapeutic potential

Expert Review of Neurotherapeutics

Volumn 9, Issue 10, 2009, Pages 1529-1545

  Moskal, Joseph R ^a   Kroes, Roger A ^a   Dawson, Glyn ^b  

^a Northwestern University   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cell surface glycoconjugate; Ganglioside; Gene therapy; Glioma; Glycosyltransferase gene; Integrin; Invasivity; Microarray

Indexed keywords

ADENOVIRUS VECTOR; ALPHA2,6 SIALYLTRANSFERASE; CARBOHYDRATE; CELL ADHESION MOLECULE; GANGLIOSIDE; GLYCOCONJUGATE; GLYCOPROTEIN; GLYCOSIDASE; GLYCOSYLTRANSFERASE; HERMES ANTIGEN; MUCIN; OLIGOSACCHARIDE; SIALIC ACID; TRANSFERASE; UNCLASSIFIED DRUG; UVOMORULIN;

BRAIN METASTASIS; BRAIN TUMOR; CANCER GROWTH; CANCER INVASION; CARBOHYDRATE ANALYSIS; CARBOHYDRATE METABOLISM; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL SURFACE; EPIGENETICS; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; REVIEW; SIALYLATION; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODIES; BRAIN NEOPLASMS; GLYCOMICS; GLYCOSYLATION; HUMANS; OLIGOSACCHARIDES;

EID: 70350170533     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.105     Document Type: Review

References (140)

1. Louis DN, Posner J, Jacobs T et al; National Cancer Institute/National Institute of Neurological Disorders and Stroke. Report of the Brain Tumor Progress Review Group. NIH, MD, USA (2000).
2. Asher A, Burger PC, Demes J et al. Facts and statistics. In: A Primer of Brain Tumors: a Patient's Reference Manual (8th Edition). American Brain Tumor Association, IL, USA (2008).
3. CBTRUS (2007-2008). Primary Brain Tumors in the United States Statistical Report 2000-2004. Central Brain Tumor Registry of the United States, IL, USA (2008).
4. SEER Pediatric Monograph, 1975-1994, Table XXVII-7.
5. Jemal A, Siegel R, Ward E et al. American Cancer Society: cancer statistics. CA Cancer J. Clin. 58(2) 71-96 (2008).
6. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61(3), 215-225 (2002). (Pubitemid 34212595)
7. Cancer Facts and Figures 2000. American Cancer Society, GA, USA (2000).
8. Yung A, Sawaya R, Curran W, Fuller G. Intracranial metastatic central nervous system tumors. In: Cancer in the Nervous System. Levin V (Ed.). Churchill Livingstone Inc., NY, USA (1996).
9. CBTRUS (2002-2003). Primary Brain Tumors in the United States Statistical Report 1995-1999. Central Brain Tumor Registry of the United States, IL, USA (2003).
10. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl Acad. Sci. USA 99(16), 10231-10233 (2002). (Pubitemid 34906955)
11. Traylor TD, Hogan EL. Gangliosides of human cerebral astrocytomas. J. Neurochem. 34(1), 126-131 (1980).
12. Fredman P, von Holst H, Collins VP et al. Potential ganglioside antigens associated with human gliomas. Neurol. Res. 8(2), 123-126 (1986). (Pubitemid 16098565)
13. Wikstrand CJ, He XM, Fuller GN et al. Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. J. Neuropathol. Exp. Neurol. 50(6), 756-769 (1991).
14. Jennemann R, Mennel HD, Bauer BL, Wiegandt H. Glycosphingolipid component profiles of human gliomas correlate with histological tumour types: analysis of inter-individual and tumourregional distribution. Acta Neurochir. 126(2-4), 170-178 (1994). (Pubitemid 24068188)
15. Jennemann R, Rodden A, Bauer BL, Mennel HD, Wiegandt H. Glycosphingolipids of human gliomas. Cancer Res. 50(23), 7444-7449 (1990).
16. Shinoura N, Dohi T, Kondo T, Yoshioka M, Takakura K, Oshima M. Ganglioside composition and its relation to clinical data in brain tumors. Neurosurgery 31(3), 541-549 (1992).
17. Pan XL, Izumi T, Yamada H, Akiyoshi K, Suenobu S, Yokoyama S. Ganglioside patterns in neuroepithelial tumors of childhood. Brain Dev. 22(3), 196-198 (2000). (Pubitemid 30256254)
18. Chang F, Li R, Noon K, Gage D, Ladisch S. Human medulloblastoma gangliosides. Glycobiology 7(4), 523-530 (1997).
19. Markowska-Woyciechowska A, Bronowicz A, Ugorski M, Gamian E, Jablonski P. Study on ganglioside composition in brain tumours supra- and infratentorial. Neurol. Neurochir. Pol. 34(6 Suppl.), 124-130 (2000).
20. Comas TC, Tai T, Kimmel D et al. Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors. Neuro. Oncol. 1(4), 261-267 (1999).
21. Popko B, Pearl DK, Walker DM et al. Molecular markers that identify human astrocytomas and oligodendrogliomas. J. Neuropathol. Exp. Neurol. 61(4), 329-338 (2002). (Pubitemid 34266784)
22. Hamasaki H, Aoyagi M, Kasama T, Handa S, Hirakawa K, Taki T. GT1b in human metastatic brain tumors: GT1b as a brain metastasis-associated ganglioside. Biochim. Biophys. Acta 1437(1), 93-99 (1999).
23. Mennel HD, Lell B. Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors. Clin. Neuropathol. 24(1), 13-18 (2005). (Pubitemid 40128782)
24. Ladisch S, Chang F, Li R, Cogen P, Johnson D. Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid. Cancer Lett. 120(1), 71-78 (1997). (Pubitemid 27483313)
25. Ladisch S, Wu ZL, Feig S et al. Shedding of GD2 ganglioside by human neuroblastoma. Int. J. Cancer 39(1), 73-76 (1987). (Pubitemid 17233830)
26. Nakamura O, Iwamori M, Matsutani M, Takakura K. Ganglioside GD3 shedding by human gliomas. Acta Neurochir. 109(1-2), 34-36 (1991).
27. Li R, Gage D, McKallip R, Ladisch S. Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2. Glycoconj. J. 13(3), 385-389 (1996). (Pubitemid 26179971)
28. Wiranowska M, Ladd S, Smith SR, Gottschall PE. CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain Cell Biol. 35(2-3), 159-172 (2006). (Pubitemid 47630628)
29. Prag S, Lepekhin EA, Kolkova K et al. NCAM regulates cell motility. J. Cell Sci. 115(Pt 2), 283-292 (2002).
30. Sasaki H, Yoshida K, Ikeda E et al. Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy. Cancer 82(10), 1921-1931 (1998).
31. Perego C, Vanoni C, Massari S et al. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J. Cell. Sci. 115(Pt 16), 3331-3340 (2002). (Pubitemid 34960185)
32. Asano K, Duntsch CD, Zhou Q et al. Correlation of N-cadherin expression in high grade gliomas with tissue invasion. J. Neurooncol. 70(1), 3-15 (2004). (Pubitemid 39193992)
33. Utsuki S, Sato Y, Oka H, Tsuchiya B, Suzuki S, Fujii K. Relationship between the expression of E-, N-cadherins and b-catenin and tumor grade in astrocytomas. J. Neurooncol. 57(3), 187-192 (2002). (Pubitemid 34692627)
34. Rorive S, Belot N, Decaestecker C et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33(3), 241-255 (2001). (Pubitemid 32219133)
35. Jung TY, Jung S, Ryu HH et al. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J. Neurosurg. 109(2), 273-284 (2008).
36. Gratsa A, Rooprai HK, Rogers JP, Martin KK, Pilkington GJ. Correlation of expression of NCAM and GD3 ganglioside to motile behaviour in neoplastic glia. Anticancer Res. 17(6B), 4111-4117 (1997). (Pubitemid 28017940)
37. Hasan SS, Ashraf GM, Banu N. Galectins - potential targets for cancer therapy. Cancer Lett. 253(1), 25-33 (2007). (Pubitemid 46887584)
38. Tucker GC. Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 8(2), 96-103 (2006).
39. Paulus W, Baur I, Beutler AS, Reeves SA. Diffuse brain invasion of glioma cells requires b 1 integrins. Lab. Invest. 75(6), 819-826 (1996). (Pubitemid 26427668)
40. Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj. J. 21(1-2), 9-15 (2004). •• Seminal paper showing that the oligosaccharides attached to integrins can play a key role in regulating their function, which involves signal transduction and intracellular phosphorylation events associated with adhesion and, thus, metastasis and invasivity in tumor cell. There are brain tumor-associated integrins. These integrins are aberrantly glycosylated. Thus, manipulating glycogene expression in brain tumors as a therapeutic strategy would be expected to affect integrins.
41. Zhao Y, Sato Y, Isaji T et al. Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J. 275(9), 1939-1948 (2008).
42. Yamamoto H, Kaneko Y, Rebbaa A, Bremer EG, Moskal JR. α2,6- Sialyltransferase gene transfection into a human glioma cell line (U373 MG) results in decreased invasivity. J. Neurochem. 68(6), 2566-2576 (1997). (Pubitemid 27218181)
43. Yamamoto H, Oviedo A, Sweeley C, Saito T, Moskal JR. A2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo. Cancer Res. 61(18), 6822-6829 (2001). •• The first report of stably transfecting a glycogene in to a human brain tumor cell in culture and demonstrating that invasivity and tumor formation in vivo had been inhibited via altered sialylation of a brain tumor-associated integrin resulting in altered focal adhesion kinase functioning. (Pubitemid 32896507)
44. Viapiano MS, Matthews RT, Hockfield S. A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J. Biol. Chem. 278(35), 33239-33247 (2003). (Pubitemid 37055773)
45. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res. 65(15), 6726-6733 (2005). (Pubitemid 41060710)
46. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res. 12(24), 7261-7270 (2006). (Pubitemid 46095397)
47. Huang PH, Mukasa A, Bonavia R et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl Acad. Sci. USA104(31), 12867-12872 (2007). (Pubitemid 47255246)
48. Rao RD, Uhm JH, Krishnan S, James CD. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front Biosci. 8, E270-E280 (2003). (Pubitemid 38918591)
49. Guo HB, Randolph M, Pierce M. Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase. J. Biol. Chem. 282(30), 22150-22162 (2007). (Pubitemid 47195758)
50. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J. Biol. Chem. 281(5), 2572-2577 (2006). (Pubitemid 43845717)
51. Scott AM, Lee FT, Tebbutt N et al. A Phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl Acad. Sci.USA 104(10), 4071-4076 (2007). (Pubitemid 47181580)
52. Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem. 266(25), 16755-16763 (1991). (Pubitemid 21907863)
53. Fish RG. Role of gangliosides in tumour progression: a molecular target for cancer therapy? Med. Hypotheses 46(2), 140-144 (1996).
54. Pilkington GJ. Glioma heterogeneity in vitro: the significance of growth factors and gangliosides. Neuropathol. Appl. Neurobiol. 18(5), 434-442 (1992).
55. Yates AJ. Glycolipids and gliomas: a review. Neurochem. Pathol. 8(3), 157-180 (1988). •• Review of the literature linking aberrant glycolipid glycosylation patterns with gliomas.
56. Brain Tumor Invasion. Mikkelsen T, Bjerkvig R, Laerum O, Rosenblum ML (Eds). Wiley Liss, New York, USA (1998).
57. Burchell B. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am. J. Pharmacogenomics 3(1), 37-52 (2003). (Pubitemid 36307061)
58. Chakraborty AK, Pawelek JM. GnT-V, macrophage and cancer metastasis: a common link. Clin. Exp. Metastasis 20(4), 365-373 (2003).
59. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj. J. 18(11-12), 841-850 (2001).
60. Drinnan NB, Halliday J, Ramsdale T. Inhibitors of sialyltransferases: potential roles in tumor growth and metastasis. Mini Rev. Med. Chem. 3(6), 501-517 (2003).
61. Kaneko Y, Yamamoto H, Kersey DS, Colley KJ, Leestma JE, Moskal JR. The expression of Gal β 1,4GlcNAc α 2,6 sialyltransferase and α 2,6-linked sialoglycoconjugates in human brain tumors. Acta Neuropathol. 91(3), 284-292 (1996). (Pubitemid 26042221)
62. Yamamoto H, Saito T, Kaneko Y et al. α2,3-sialyltransferase mRNA and α2,3-linked glycoprotein sialylation are increased in malignant gliomas. Brain Res. 755(1), 175-179 (1997). (Pubitemid 27192015)
63. Yamamoto H, Swoger J, Greene S et al. β1,6-N-acetylglucosamine- bearing N-glycans in human gliomas: implications for a role in regulating invasivity. Cancer Res. 60(1), 134-142 (2000). (Pubitemid 30058743)
64. Dawson G, Moskal JR, Dawson SA. Transfection of 2,6 and 2,3-sialyltransferase genes and GlcNAc-transferase genes into human glioma cell line U-373 MG affects glycoconjugate expression and enhances cell death. J. Neurochem. 89(6), 1436-1444 (2004). (Pubitemid 38802665)
65. Xu S, Zhu X, Zhang S et al. Overexpression of β-1,4- galactosyltransferase I, II, and V in human astrocytoma. J. Cancer Res. Clin. Oncol. 127(8), 502-506 (2001).
66. Hoon DS, Kuo CT, Wen S et al. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. Am. J. Pathol. 159(2), 493-500 (2001). (Pubitemid 32751080)
67. Bevilacqua M, Butcher E, Furie B et al. Selectins: a family of adhesion receptors. Cell 67(2), 233 (1991).
68. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60, 443-475 (1991).
69. Goss PE, Reid CL, Bailey D, Dennis JW. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin. Cancer Res. 3(7), 1077-1086 (1997). (Pubitemid 27319753)
70. Becker R, Eichler MK, Jennemann R, Bertalanffy H. Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate. Br. J. Neurosurg. 16(3), 269-275 (2002). (Pubitemid 34888548)
71. Fujimoto Y, Izumoto S, Suzuki T et al. Ganglioside GM3 inhibits proliferation and invasion of glioma. J. Neurooncol. 71(2), 99-106 (2005). (Pubitemid 40796289)
72. Ishikawa D, Kikkawa H, Ogino K, Hirabayashi Y, Oku N, Taki T. GD1α-replica peptides functionally mimic GD1α, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis. FEBS Lett. 441(1), 20-24 (1998). (Pubitemid 29012364)
73. Hanessian S, Zhan L, Bovey R, Saavedra OM, Juillerat-Jeanneret L. Functionalized glycomers as growth inhibitors and inducers of apoptosis in human glioblastoma cells. J. Med. Chem. 46(17), 3600-3611 (2003). (Pubitemid 36992205)
74. Abad-Rodriguez J, Bernabe M, Romero-Ramirez L, Vallejo-Cremades M, Fernandez-Mayoralas A, Nieto-Sampedro M. Purification and structure of neurostatin, an inhibitor of astrocyte division of mammalian brain. J. Neurochem. 74(6), 2547-2556 (2000). (Pubitemid 30314232)
75. Aguilera B, Romero-Ramirez L, Abad-Rodriguez J, Corrales G, Nieto- Sampedro M, Fernandez-Mayoralas A. Novel disaccharide inhibitors of human glioma cell division. J. Med. Chem. 41(23), 4599-4606 (1998). (Pubitemid 28516458)
76. Vallejo-Cremades M, Nieto-Sampedro M. Neurostatin: cellular sources and cellular targets of the inhibitor. Neuron Glia. Biol. 2(2), 115-123 (2006).
77. Rebbaa A, Chou PM, Bremer EG. Modulation of growth factor response in brain tumors by complex carbohydrates. Bull. Cancer 91(4), E15-E60 (2004).
78. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56(23), 5309-5318 (1996). •• Discusses ideas about the linkage between tumor malignancy and aberrant glycosylation. The focus is on glycosphingolipids but the ideas provide the foundation for the concept of a functional role for oligosaccharides in malignancy, metastasis and invasivity. (Pubitemid 27011703)
79. Harduin-Lepers A, Mollicone R, Delannoy P, Oriol R. The animal sialyltransferases and sialyltransferase-related genes: a phylogenetic approach. Glycobiology 15(8), 805-817 (2005). (Pubitemid 41417983)
80. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie 83(8), 727-737 (2001).
81. Kitagawa H, Paulson JC. Differential expression of five sialyltransferase genes in human tissues. J. Biol. Chem. 269(27), 17872-17878 (1994). (Pubitemid 24206176)
82. Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 58(18), 4066-4070 (1998). (Pubitemid 28440556)
83. Peyrat JP, Recchi MA, Hebbar M et al. Regulation of sialyltransferase expression by estradiol and 4-OH-tamoxifen in the human breast cancer cell MCF-7. Mol. Cell Biol. Res. Commun. 3(1), 48-52 (2000). (Pubitemid 30190564)
84. Julien S, Krzewinski-Recchi MA, Harduin-Lepers A et al. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc α2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj. J. 18(11-12), 883-893 (2001). (Pubitemid 36315053)
85. Marcos NT, Pinho S, Grandela C et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 64(19), 7050-7057 (2004). (Pubitemid 39331016)
86. Grimes WJ. Glycosyltransferase and sialic acid levels of normal and transformed cells. Biochemistry 12(5), 990-996 (1973).
87. Nicolson GL. Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells. Biochim. Biophys. Acta 695(2), 113-176 (1982).
88. Roth J. Cellular sialoglycoconjugates: a histochemical perspective. Histochem. J. 25(10), 687-710 (1993).
89. Schirrmacher V, Altevogt P, Fogel M et al. Importance of cell surface carbohydrates in cancer cell adhesion, invasion and metastasis: does sialic acid direct metastatic behaviour? Invasion Metastasis 2, 313-360 (1982). (Pubitemid 13135742)
90. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3(2), 97-130 (1993). • Thorough review of the literature pertaining to all of the oligosaccharide functions in vertebrate cells. (Pubitemid 23132602)
91. Warren L, Fuhrer JP, Buck CA. Surface glycoproteins of normal and transformed cells: a difference determined by sialic acid and a growth-dependent sialyl transferase. Proc. Natl Acad. Sci. USA 69(7), 1838-1842 (1972).
92. Collard JG, Schijven JF, Bikker A, La Riviere G, Bolscher JG, Roos E. Cell surface sialic acid and the invasive and metastatic potential of T-cell hybridomas. Cancer Res. 46(7), 3521-3527 (1986). (Pubitemid 16096901)
93. Passaniti A, Hart GW. Cell surface sialylation and tumor metastasis: metastatic potential of B16 melanoma variants correlates with their relative numbers of specific penultimate oligosaccharide structures. J. Biol. Chem. 263(16), 7591-7603 (1988). • Established that not only are cell-surface oligosaccharides aberrantly expressed in transformed cells, but that cell surface sialylation could be correlated with metastatic potential. Malignant brain tumors that arise in the brain are not metastatic, they do not leave the brain. However they are highly invasive within the brain. It is likely that many of the same mechanisms that govern metastasis also control invasivity. Moreover, tumor cell metastasis to the brain accounts for approximately 200,000 new brain tumors per year compared with approximately 20,000 newly diagnosed glioblastomas.
94. Werkmeister JA, Pross HF, Roder JC. Modulation of K562 cells with sodium butyrate: association of impaired NK susceptibility with sialic acid and analysis of other parameters. Int. J. Cancer 32(1), 71-78 (1983).
95. Broquet P, Baubichon-Cortay H, George P, Peschard MJ, Louisot P. Effect of desipramine on a glycoprotein sialyltransferase activity in C6 cultured glioma cells. J. Neurochem. 54(2), 388-394 (1990). (Pubitemid 20044285)
96. Broquet P, George P, Geoffroy J, Reboul P, Louisot P. Study of O-glycan sialylation in C6 cultured glioma cells: evidence for post-translational regulation of a β-galactoside α 2,3 sialyltransferase activity by N-glycosylation. Biochem. Biophys. Res. Commun. 178(3), 1437-1443 (1991).
97. Moskal JR, Gardner DA, Basu S. Changes in glycolipid glycosyltransferases and glutamate decarboxylase and their relationship to differentiation in neuroblastoma cells. Biochem. Biophys. Res. Commun. 61(2), 751-758 (1974).
98. Reboul P, Broquet P, George P, Louisot P. Effect of retinoic acid on two glycosyltransferase activities in C6 cultured glioma cells. Int. J. Biochem. 22(8), 889-893 (1990). (Pubitemid 20285829)
99. Stoykova LI, Glick MC. Purification of an α-2,8-sialyltransferase, a potential initiating enzyme for the biosynthesis of polysialic acid in human neuroblastoma cells. Biochem. Biophys. Res. Commun. 217(3), 777-783 (1995).
100. Shen AL, Chou MD, Chi CW, Lee LS. Alterations in serum sialyltransferase activities in patients with brain tumors. Surg. Neurol. 22(5), 509-514 (1984).
101. Gornati R, Basu S, Montorfano G, Berra B. Glycosyltransferase activities in human meningiomas: preliminary results. Cancer Biochem. Biophys. 15(1), 1-10 (1995).
102. Yamamoto H, Kaneko Y, Vandermulen D et al. The expression of CMP-NeuAc: Gal β 1,4GlcNAc α 2,6 sialyltransferase [EC 2.4.99.1] and glycoproteins bearing α 2,6-linked sialic acids in human brain tumours. Glycoconj. J. 12(6), 848-856 (1995). (Pubitemid 26018881)
103. Wen DX, Livingston BD, Medzihradszky KF, Kelm S, Burlingame AL, Paulson JC. Primary structure of Gal β 1,3(4)GlcNAc α 2,3-sialyltransferase determined by mass spectrometry sequence analysis and molecular cloning. Evidence for a protein motif in the sialyltransferase gene family. J. Biol. Chem. 267(29), 21011-21019 (1992).
104. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473(1), 21-34 (1999). • Key paper linking oligosaccharides and tumor progression.
105. Varki A. Glycosylation changes in cancer. In: Essentials of Glycobiology. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. (Eds). Cold Spring Harbor Laboratory Press, NY, USA 535-549 (1999).
106. Luo J, Isaacs WB, Trent JM, Duggan DJ. Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer Invest. 21(6), 937-949 (2003). (Pubitemid 38055990)
107. Luo Z, Geschwind DH. Microarray applications in neuroscience. Neurobiol. Dis. 8(2), 183-193 (2001).
108. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 22(42), 6497-6507 (2003). (Pubitemid 37376427)
109. Kemmner W, Roefzaad C, Haensch W, Schlag PM. Glycosyltransferase expression in human colonic tissue examined by oligonucleotide arrays. Biochim. Biophys. Acta 1621(3), 272-279 (2003). (Pubitemid 36638580)
110. Kroes RA, Panksepp J, Burgdorf J, Otto NJ, Moskal JR. Modeling depression: social dominance-submission gene expression patterns in rat neocortex. Neuroscience 137(1), 37-49 (2006). (Pubitemid 43031473)
111. Russell & Rubinstein's; Pathology of Tumors of the Nervous System, Sixth Edition. Bigner DD, McLendon RE, Bruner JM (Eds). Arnold, NY, USA (1998)
112. Churchill GA. Fundamentals of experimental design for cDNA microarrays. Nat. Genet. 32(Suppl.), 490-495 (2002).
113. Kroes RA, Dawson G, Moskal JR. Focused microarray analysis of glycogene expression in human glioblastomas. J. Neurochem. 103(Suppl. 1), 14-24 (2007).
114. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 395(6697), 89-93 (1998). (Pubitemid 28420236)
115. Gonzalo S, Jaco I, Fraga MF et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat. Cell Biol. 8(4), 416-424 (2006).
116. Hansen RS, Wijmenga C, Luo P et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc. Natl Acad. Sci. USA 96(25), 14412-14417 (1999). (Pubitemid 30000664)
117. Maraschio P, Zuffardi O, Dalla Fior T, Tiepolo L. Immunodeficiency, centromeric heterochromatin instability of chromosomes 1, 9, and 16, and facial anomalies: the ICF syndrome. J. Med. Genet. 25(3), 173-180 (1988). (Pubitemid 18082764)
118. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3), 247-257 (1999). (Pubitemid 29519904)
119. Trasler JM, Trasler DG, Bestor TH, Li E, Ghibu F. DNA methyltransferase in normal and Dnmtn/Dnmtn mouse embryos. Dev. Dyn. 206(3), 239-247 (1996). (Pubitemid 26226869)
120. Xu GL, Bestor TH, Bourc'his D et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402(6758), 187-191 (1999).
121. Costello JF. DNA methylation in brain development and gliomagenesis. Front. Biosci. 8, S175-S184 (2003).
122. Fan G, Beard C, Chen RZ et al. DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J. Neurosci. 21(3), 788-797 (2001). (Pubitemid 32163120)
123. Kawai J, Hirotsune S, Hirose K, Fushiki S, Watanabe S, Hayashizaki Y. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res. 21(24), 5604-5608 (1993). (Pubitemid 24003084)
124. Kazazian HH Jr, Moran JV. The impact of L1 retrotransposons on the human genome. Nat. Genet. 19(1), 19-24 (1998).
125. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69(6), 915-926 (1992).
126. Takizawa T, Nakashima K, Namihira M et al. DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Dev. Cell 1(6), 749-758 (2001). (Pubitemid 33586130)
127. Baylin S, Bestor TH. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1(4), 299-305 (2002). (Pubitemid 41039130)
128. Costello JF, Plass C. Methylation matters. J. Med. Genet. 38(5), 285-303 (2001).
129. Feinberg AP. Cancer epigenetics is no mickey mouse. Cancer Cell 8(4), 267-268 (2005).
130. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
131. Kawamura YI, Toyota M, Kawashima R et al. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 135(1), 142-151 E143 (2008). (Pubitemid 351899013)
132. Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal study group. J. Clin. Oncol. 25(7), 837-844 (2007). (Pubitemid 350002884)
133. Sonabend AM, Ulasov IV, Lesniak MS. Conditionally replicative adenoviral vectors for malignant glioma. Rev. Med. Virol. 16(2), 99-115 (2006).
134. Piao Y, Jiang H, Alemany R et al. Oncolytic adenovirus retargeted to δ-EGFR induces selective antiglioma activity. Cancer Gene Ther. 16(3), 256-265 (2009).
135. Fueyo J, Alemany R, Gomez-Manzano C et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl Cancer Inst. 95(9), 652-660 (2003). (Pubitemid 36603721)
136. Fueyo J, Gomez-Manzano C, Alemany R et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1), 2-12 (2000). (Pubitemid 30066345)
137. Paulson JC, Weinstein J, Schauer A. Tissue-specific expression of sialyltransferases. J. Biol. Chem. 264(19), 10931-10934 (1989). • The first analysis using cDNA clones of various sialyltransferases, including the N-linked glycoprotein α2,6 sialyltransferase that formed the cornerstone to the glycogene expression studies associated with brain tumor therapeutics. Also provides the key references for the cloning and expression studies of sialyltransferase family of genes.
138. Alavi A, Axford JS. Sweet and sour: the impact of sugars on disease. Rheumatology (Oxford) 47(6), 760-770 (2008). (Pubitemid 351796358)
139. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8(3), 226-234 (2009). • Excellent review of recent investigations into enhancing the specificity and efficacy of antibodies that have therapeutic potential. This article underscores how oligosaccharide structure and function can impact molecular function and is a novel approach to glycobiology-based approaches for the treatment of cancer.
140. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim. Biophys. Acta 1780(3), 546-563 (2008). • An important article that addresses the idea of manipulating the glycosylation of mucins with the aim of developing cancer vaccines. It underscores the importance of the oligosaccharide moieties of cell-surface glycoproteins in immune surveillance and potential ways, by manipulating glycosylation directly, that autoantibody formation might be inhibited. Some interesting applications of site-specific glycosylation are also discussed.